SCHEMBL219341

SCHEMBL219341

Clc1ccccc1N1CC[N]CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.59
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 1/20 0.50
PLA2G1B P04054 1/20 0.50
RAB9A P51151 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
LMNA P02545 2/20 0.46
HTT P42858 1/20 0.46
AKR1C3 P42330 1/20 0.45
DRD2 P14416 3/20 0.44
DRD3 P35462 3/20 0.44
DRD4 P21917 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA1B P35368 1/20 0.44
NOTUM Q6P988 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364203 0.86 DRD2 (0.62) ADRB1DRD2DRD3DRD4NOTUM
SCHEMBL28396664 0.84 ADRB1 (0.71) ADRB1KDM4EALDH1A1PLA2G1BRAB9A
SCHEMBL5426332 0.83 DRD2 (0.46) ADRB1KDM4EALDH1A1LMNADRD2
SCHEMBL30407939 0.79 ADRB1 (0.65) ADRB1KDM4EALDH1A1PLA2G1BRAB9A
SCHEMBL1825806 0.79 ADRB1 (0.65) ADRB1KDM4EALDH1A1PLA2G1BRAB9A
SCHEMBL9820624 0.79 DRD2 (0.42) ADRB1DRD2DRD3DRD4HTR1A
SCHEMBL7286192 0.78 NOTUM (0.43) ADRB1KDM4EALDH1A1DRD2DRD3
SCHEMBL9655124 0.77 ADRB1 (0.63) ADRB1KDM4EALDH1A1PLA2G1BRAB9A
SCHEMBL10893618 0.77 ADRB1 (0.63) ADRB1KDM4EALDH1A1PLA2G1BRAB9A
SCHEMBL217611 0.77 ADRB1 (0.60) ADRB1ALDH1A1LMNAHTTAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981131-B2 Tricyclic compounds for the treatment of inflammatory disorders Piramal Enterprises Limited (IN) 2015-03-17 US claimed
US-20110009396-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS Piramal Enterprises Limited (IN) 2011-01-13 US claimed
US-7700628-B2 Aromatic ether derivatives useful as thrombin inhibitors ELI LILLY AND COMPANY (US) 2010-04-20 US claimed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO claimed
EP-1817287-B1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS LILLY CO ELI (US) 2010-02-10 EP claimed
US-20090227566-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS ELI LILLY AND COMPANY 2009-09-10 US claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
EP-2051978-A2 ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2009-04-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
WO-2009016565-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS PIRAMAL LIFE SCIENCES LIMITED (IN) 2009-02-05 WO claimed
WO-2007136875-A2 ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-11-29 WO claimed
EP-1817287-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS Eli Lilly and Company (US) 2007-08-15 EP claimed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 WO claimed
WO-2006057845-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS ELI LILLY AND COMPANY (US) 2006-06-01 WO claimed
WO-2005075477-A1 ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 2005-08-18 WO claimed
EP-0853617-A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES Novartis AG (CH) 1998-07-22 EP claimed
WO-1997008155-A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES NOVARTIS AG (CH) 1997-03-06 WO claimed
US-4556656-A HYPOTENSIVE, ANTIPSYCHOTIC, DIABETIC, AND ANALGESIC AGENTS THE UPJOHN COMPANY (US) 1985-12-03 US claimed
US-4390697-A Process for the preparation of triazoloquinazolinones ROUSSEL UCLAF (FR) 1983-06-28 US claimed
US-4350695-A Antihistaminic and bronchospasmolytic triazoloquinazolinones ROUSSEL UCLAF (FR) 1982-09-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R ADRB1 136/4885KDM4E 2981/4885ALDH1A1 1731/4885
US-20110009396-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS IL1R1, IL1B, IL1A ADRB1 271/4885KDM4E 4136/4885ALDH1A1 1115/4885
US-20090227566-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS TFPI, F2, F11 ADRB1 570/4885KDM4E 1557/4885ALDH1A1 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.